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httpcense.Abstract Gastroesophageal reﬂux (GER) is a common disorder in children with bronchial asthma.
It has been identiﬁed as a potential trigger, complication and even differential diagnosis for asthma.
Our aim was to ﬁnd out the efﬁcacy of the combined use of both the proton pump inhibitor esomep-
razole and the antidopaminergic prokinetic domperidone versus the sole use of esomeprazole in
improving asthma severity in children with difﬁcult to treat asthma.
Patients and methods: Among 178 children with difﬁcult-to-treat asthma, GER was assessed
using upper GIT endoscopy. Those who had GER were randomly divided into 2 equal subgroups
the ﬁrst was treated with esomeprazole for 12 weeks while the other was treated with esomeprazole
and domperidone for the same period (beside the usual treatment for asthma in both groups).
Childhood-asthma control test (C-ACT), forced expiratory volume in 1st second (FEV1) [% of
predicted], peak expiratory ﬂow (PEF) variability, induced sputum substance P (SP) and endoscopic
reﬂux score (ERS) were recorded before and after the treatment.
Results: Gastro-esophageal reﬂux (GER) was observed in about 45% of children with difﬁcult-
to-treat asthma. The C-ACT, induced sputum SP, ERS and FEV1 showed signiﬁcant improvement
while PEF variability showed no signiﬁcant changes when comparing combination therapy
subgroup (esomeprazole and domperidone) with esomeprazole only subgroup.5611515.
(A.S. Bediwy).
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34 A.S. Bediwy et al.Conclusions: Combination of domperidone and esomeprazole was more effective in improving
the endoscopic reﬂux score, childhood-asthma control test (C-ACT) and FEV1 (% of predicted)
and signiﬁcantly reduced the sputum SP than the use of esomeprazole only in children with
difﬁcult-to-treat asthma.
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Gastroesophageal reﬂux (GER) is a common ﬁnding in
asthmatic children and has been identiﬁed as a potential trig-
ger for asthma. GER is thought to affect asthma through
the activation of vagal reﬂexes and/or microaspiration [1].
Previously, we found that the use of esomeprazole was
effective in improving asthma symptoms as indicated by child-
hood-asthma control test (C-ACT), however it had insigniﬁ-
cant effects on lung function as indicated by FEV1 and peak
expiratory ﬂow variability [2]. Another previous study showed
the efﬁcacy of the combined use of omeprazole and domperi-
done in improving asthma in adult patients with asthma and
gastroesophageal reﬂux [3].
This stimulated us to investigate the efﬁcacy of the com-
bined use of both esomeprazole and antidopaminergic proki-
netic domperidone versus the sole use of esomeprazole in
improving asthma severity as indicated by C-ACT, FEV1,
PEF variability and induced sputum levels of SP in children
having difﬁcult to treat asthma with GER.
Patients and methods
The study included 178 children between 6 and 10 years of age
(diagnosed with difﬁcult-to-treat bronchial asthma) and
attending the Asthma Clinic of Pediatric and Pulmonology
Departments at International Hospital of Bahrain, a tertiary
care hospital, Kingdom of Bahrain. Patients were identiﬁed
from the clinic database according to the guidelines of the Na-
tional Asthma Education and Prevention Program [4].
The inclusion criteria of the study at screening included the
following:
1- Asthma was diagnosed based on the symptoms, family
history, and documented with the presence of reversible
airﬂow obstruction (increase FEV1 by more than 12%
after inhaled short acting ß2-agonist) and PEF variabil-
ity P20%.
2- Difﬁcult-to-treat asthma was identiﬁed if the child has
persistent refractory symptoms, was receiving mainte-
nance therapy of inhaled steroids (P400 lg beclometha-
sone dipropionate or equivalent per day) and long acting
ß2-agonist and had received at least one course of sys-
temic steroids in the preceding 12 months [5,6].
Exclusion criteria included the following:
1. Other chronic lung disease or systemic medical condition
other than asthma, GER, allergic rhinitis or atopic
dermatitis.
2. Using anti-reﬂux medications in the preceding 6 months
before enrollment into the study.3. Concurrent use of other medications that can affect the
gastrointestinal motility.
4. Known hypersensitivity to esomeprazole or
domperidone.
5. Children with long QT syndrome by pre-enrollment
ECG study [7].
6. Enrollment in our previous study [2].
Study design
Children having difﬁcult-to-treat-asthma were subjected to
upper GIT endoscopy and were subsequently divided into
two groups according to the presence or absence of GER.
The group with GER was further double blindly randomly di-
vided into two equal subgroups. The ﬁrst subgroup received
anti-reﬂux therapy in the form of proton pumps inhibitors
[PPI] (Esomeprazole capsule 2 mg/kg/day) for 12 weeks beside
the usual anti-asthma medications as mentioned before. The
second subgroup received combined anti-reﬂux therapy in
the form of proton pumps inhibitors (PPI) (Esomeprazole cap-
sule 2 mg/kg/day) plus antidopaminergic gastroprokinetic
drug (Domperidone 0.5 mg/kg of body weight) for 12 weeks
beside the usual anti-asthma medications as mentioned before.
The group of children who had difﬁcult-to-treat asthma with-
out reﬂux received placebo identical appearing capsules con-
taining lactose (placebo capsule/day) for 12 weeks beside the
usual anti-asthma medications as mentioned before. This pla-
cebo treatment was given to asthmatic patients without GER
to rule out the placebo effect on improvement in the other
group and to exclude the effect of better patient adherence
to prescribed medications and better follow up by regular
attendance to the clinic.
All asthmatic children had a pre-study phase of 6 month
duration during which they were selected for eligibility for
the study and to reach maximum asthma control according
to the guidelines of the National Asthma Education and Pre-
vention Program [4]. During this pre-study phase; all children
were screened for Helicobacter pylori infection and the positive
cases received metronidazole and clatrithromycin beside the
esomeprazole (triple therapy). All children had chest X-ray
postero-anterior and lateral views to exclude other lung dis-
eases and abdominal ultrasonography was done when needed
to exclude organomegaly. Pre-study ECG was done for all
children to exclude the presence of long QT syndrome.
All children included in the study had detailed history tak-
ing and thorough clinical examination with special stress on:
GIT symptoms suggestive of reﬂux including heart burn, acid
regurgitation and food regurgitation. Childhood-asthma con-
trol test (C-ACT), pulmonary function test, and induced spu-
tum substance P were done before and after the treatment
phase for all the children. All the children had upper gastroin-
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evaluate the presence or absence of GER, to classify the
groups and to assess the severity of GER. Only the children
who proved to have GER had another upper gastrointestinal
endoscopic study at the end of the treatment phase, to evaluate
the response for both types of anti-GER treatment.
Childhood-asthma control test (C-ACT) is a seven-item
child- and caregiver-completed tool with a scoring range of
0–27; higher scores indicate better control. A score of 19 or less
indicates that the asthma may not be well controlled. The C-
ACT is intended for use in children up to the age of 12 years
[8,9].
Pulmonary functions and spirometry were done for all
cases using calibrated computerized machine (Jaeger Master-
Screen-Body/Diffusion, Jaeger, Germany) with special stress
on FEV1 (% of predicted), and peak expiratory ﬂow (PEF)
variability. The PEF variability was calculated as the percentile
ratio of the difference between maximum and minimum PEF
to the mean daily PEF over a period of one week i.e. (maxi-
mum PEF  minimum PEF)/(mean of all PEFs over
1 week) · 100 [10].
Induced-sputum was produced and collected either sponta-
neously or induced with hypertonic saline nebulization from
all subjects. Prior to sputum induction, children inhaled
200 lg of salbutamol to minimize broncho-constriction during
the induction procedure. Sputum was induced by inhalation of
3% hypertonic saline solution for 5 min using an ultrasonic
nebulizer, and the subjects were encouraged to cough and
expectorate sputum into sterile containers. FEV1 was mea-
sured after nebulization. Nebulization was stopped if a fall
in FEV1 of >20% compared to baseline values occurred or
if troublesome symptoms appeared [9].
Sputum substance P (SP) measurement: SP was measured
using a commercially available enzyme linked immunosorbent
assay (ELISA) (R&D Systems, Oxon, UK). It has no signiﬁ-
cant cross-reactivity with neurokinin A, neurokinin B or neu-
ropeptide K. The limit of detection of this assay is 0.06 ng/ml.
Upper gastrointestinal endoscopy was done in all cases with
difﬁcult-to-treat asthma to document or exclude the presence
of GER using Olympus GIF-P140 Pediatric Video Gastro-
scope with 8.5 mm diameter, and 2.2 mm channel. The endo-
scopic diagnostic criteria of esophagitis followed Los Angeles
classiﬁcation grading: grade A (score 1): 1 or more mucosal
breaks each 65 mm in length. Grade B (score 2): At least
one mucosal break >5 mm long, but not continuous between
the tops of adjacent mucosal folds. Grade C (score 3): At least
one mucosal break that is continuous between the tops of adja-
cent mucosal folds. Grade D (score 4): Mucosal break that in-
volves at least three-fourth of the luminal circumferences.
Patient took score 0 if there were no features of reﬂux [11].
Parents of all included children subjects signed a written in-
formed consent before enrollment into the study. The local
Institutional Research Ethics Committee approved the study
protocol.
Statistical analysis
The power level of the number of cases in the study was more
than 85%. Statistical analysis was performed with Statistical
Package for Social Sciences (SPSS), version 16.0 (Chicago,
IL, USA). Data are presented as mean (±SD) values. Com-parison between the studied groups was performed with
Student t-test, with P< 0.05 was considered statistically sig-
niﬁcant. Wilcoxon’s signed rank test was used to assess the
normality of distributions of the data. The Bonferroni correc-
tion/adjustment procedure was done to avoid ‘‘signiﬁcance’’
due to chance only; in multiple comparison with many param-
eters. Correlation between variables was evaluated using
Pearson’s correlation coefﬁcient. Chi-square was used to com-
pare percentages (e.g. male to female ratio).
Results
The demographic data of patients groups and subgroups as
well as their clinical data are shown in Tables 1 and 2.
Gastro-esophageal reﬂux (GER) was found in 80 out of 178
children with difﬁcult to treat bronchial asthma (45%).
There was no signiﬁcant difference in age and sex in
children with difﬁcult to treat asthma with and without
GER. However, the body mass index (BMI) was signiﬁcantly
lower in the patient group with GER than asthmatic children
without GER. Table 1 also showed that there were no signiﬁ-
cant differences in the blood eosinophils, C-ACT, FEV1 (% of
predicted), and PEF variability, but the sputum SP was signif-
icantly higher in children with difﬁcult-to-treat asthma and
GER than in children with difﬁcult-to-treat asthma without
GER.
Table 2 showed the demographic and clinical data of the
two subgroups of children with difﬁcult-to-treat asthma and
GER who were treated for GER with either esomeprazole
alone or with both esomeprazole and domperidone. There
was no signiﬁcant difference in age, sex, BMI, C-ACT, PEF
variability, FEV1 (% of predicted) and the sputum SP between
the two subgroups.
Table 3 showed the effect of 12 weeks of anti-GER treat-
ment on children with difﬁcult-to-treat asthma and GER when
compared to children with difﬁcult-to-treat asthma without
GER and received placebo treatment to overcome the placebo
effects. It showed signiﬁcant reduction of blood eosinophils
(%), improvement of C-ACT and FEV1 (% of predicted) with
signiﬁcant reduction of sputum SP after treatment than before
treatment. However, PEF variability showed no signiﬁcant
changes.
Table 4 showed signiﬁcant reduction of both blood eosino-
phils (%) and sputum SP and improvement of C-ACT in the
subgroup treated with both esomeprazole and domperidone
than asthmatic children treated with esomeprazole. Also the
FEV1 (% of predicted) showed a signiﬁcant improvement in
the subgroup treated with both esomeprazole and domperi-
done (P= 0.047). On the other hand, despite the improvement
of endoscopic reﬂux scores in the subgroup with difﬁcult-to-
treat asthma and GER who was treated with both esomepraz-
ole and domperidone than the subgroup with GER and treated
with esomeprazole only, but it was of no statistical
signiﬁcance.
In children subgroup who were treated with esomeprazole,
there were 14 children with grade A (35%), 8 children with
grade B (20%), 8 children with grade C (40%), and 10 children
with grade D (25%). After 12 weeks of esomeprazole therapy;
there were 14 with no evidence of GER disease, 8 children with
grade A (20%), 8 children with grade B (20%), 10 children
with grade C (25%), and no children with grade D (0%).
Table 1 Demographic data, C-ACT, FEV1; PEF variability and induced sputum SP in asthmatic children with and without GER.
Asthmatic without GER (n= 98) Asthmatic with GER (n= 80) t P
Age 8 ± 1.4 7.9 ± 1.3 0.2 0.8
BMI 19.5 ± 1.4 20.6 ± 2.4 6.1 0.003*
M/F 1.2:1 1:1 v2 = 1.7 0.5
Age at diagnosis 3.9 ± 1.4 3.1 ± 0.9 2.7 0.008*
Associated nasal allergy 52 (53%) 44 (58%) v2 = 2.0 0.4
Atopic dermatitis 42 (43%) 38 (47%) v2 = 2.7 0.3
Immediate family history of Asthma 60 (61%) 46(60%) v2 = 1.8 0.45
Blood eosinophils (%) 6 ± 1.4 5.9 ± 2.0 0.48 0.63
C-ACT 12.4 ± 3.4 12.8 ± 3.9 0.36 0.72
FEV1 (% of predicted) 59.6 ± 4.4 58.1 ± 7.3 1.1 0.27
PEF variability (%) 39.45 ± 3.5 40.3 ± 5.2 1.02 0.31
Sputum SP (pg/ml) 1069.75 ± 58.9 1385.6 ± 208 9.3 <0.001*
Reference GER score 2.57 ± 1.17
* signiﬁcant.
Table 2 Demographic data, C-ACT, FEV1; PEF variability and induced sputum SP in the 2 subgroups of asthmatic children with
GER before starting 2 types of anti-GER treatment.
Esomeprazole subgroup (n= 40) Esomeprazole and domperidone subgroup (n= 40) t P
Age 7.75 ± 1.25 8.1 ± 1.3 0.8 0.4
BMI 20.5 ± 2.7 20.7 ± 2.1 0.26 0.79
M/F 1.2:1 1:1 v2 = 1.6 0.6
Blood eosinophils (%) 5.95 ± 1.7 5.9 ± 2.3 0.07 0.94
C-ACT 12.9 ± 4.4 12.7 ± 3.6 0.17 0.8
FEV1 (% of predicted) 58.5 ± 8.3 57.6 ± 6.2 0.4 0.6
PEF variability (%) 40.4 ± 5.8 40.2 ± 4.5 0.1 0.9
Sputum SP (pg/ml) 1424.5 ± 175.7 1325.3 ± 231 1.9 0.06
Table 3 The C-ACT, FEV1; PEF variability and induced sputum SP in asthmatic children with and without GER after treatment
phase.
Asthmatic with GER
(active treatment phase) (n= 80)
Asthmatic without GER
(placebo treatment phase) (n= 98)
t P
Blood eosinophils (%) 3.7 ± 1.5 4.5 ± 1.1 3.1 0.004*
C-ACT 18.1 ± 4.1 12.9 ± 3.1 5.9 <0.001*
FEV1 (% of predicted) 67.9 ± 7.3 60.5 ± 4.5 5.1 <0.001*
PEF variability (%) 38.3 ± 5.3 38.5 ± 3.5 0.19 0.84
Sputum SP (pg/ml) 1224 ± 209 969.7 ± 59 7.4 <0.001*
* signiﬁcant.
Table 4 The C-ACT, FEV1; PEF variability and induced sputum SP in the 2 subgroups of asthmatic children with GER after starting
2 types of anti-GER treatment.
Esomeprazole subgroup (n= 40) Esomeprazole & Domperidone subgroup (n= 40) t P
Blood eosinophils (%) 4.4 ± 1.6 3.05 ± 0.9 3.4 0.003*
C-ACT 17.4 ± 3.5 19.758 ± 2.7 2.6 0.02*
FEV1 (% of predicted) 66.05 ± 8.3 69.75 ± 6.2 2.1 0.047
*
PEF variability (%) 39.55 ± 5.7 37.1 ± 4.6 1.6 0.12
Sputum SP (pg/ml) 1242.75 ± 185.4 1130.3 ± 174 2.1 0.02*
Reference GER score 1.35 ± 1.2 0.85 ± 0.81 1.3 0.18
* signiﬁcant.
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and domperidone, and before starting the treatment there were
6 children with grade A (15%), 10 children with grade B
(25%), 10 children with grade C (25%), and 14 children withgrade D (35%). After 12 weeks of esomeprazole and domper-
idone therapy; there were 16 with no evidence of GER disease
(40%), 14 children with grade A (35%), 10 children with grade
B (25%), and no children with grades C or D (0%).
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GER is a common ﬁnding in asthmatic children. It may be just
an associated disorder or may be caused or aggravated by
asthma. There are different mechanisms that worsen GER in
asthma. Asthma increases the pressure gradient between the
thorax and the abdomen, decreases the lower esophageal
sphincter pressure and lengthens the time needed to perform
esophageal clearance and hence increases the GER severity
[12]. The asthma medications also increase the GER severity.
Beta agonists and theophyllin reduce lower esophageal sphinc-
ter tone and increase gastric acid secretion [13] while systemic
steroids increase esophageal acid contact times [12]. On the
other hand GER worsen asthma status through vagally medi-
ated esophageal tracheobronchial cough reﬂex, a local axonal
reﬂex, heightened bronchial reactivity, and micro- or macro-
aspiration into tracheobronchial tree [14,15].
Patients with difﬁcult-to-treat asthma have increased inci-
dence of GER with much greater prevalence of GER symp-
toms than the general population. In the current study, we
found that 80 out of 178 (45%) children with difﬁcult-to-treat
asthma had GER. This conﬁrmed our previous ﬁnding where
we found an increased incidence of GER in children with dif-
ﬁcult-to-treat asthma (49%) [2]. Other studies showed that the
incidence of GER in such cases varies between 19.3% and 80%
according to the method of reporting of GER and the individ-
ual characteristics [16].
Proper identiﬁcation and treatment of asthma-associated
GER is of vital importance for proper management of such
cases. In the current study we found a signiﬁcantly higher level
of the induced-sputum substance P in asthmatic children with
GER than in those without GER which conﬁrms the data pre-
sented in our previous study [2]. These ﬁndings agreed with the
work of Patterson et al. [17], who found that sputum SP was
signiﬁcantly higher in adult asthmatic patients with reﬂux than
in adult asthmatic patients without reﬂux [17]. This substance
plays an important role in the development of asthma-associ-
ated inﬂammation. It has a potent effect on the bronchomotor
tone, airway secretion, bronchial circulation (vasodilatation
and microvascular leakage) as well as on inﬂammatory and im-
mune cells [18]. Presence of higher levels of sputum SP can
guess the presence of associated GER.
The current study was mainly planned to ﬁnd an answer to
the question about the efﬁcacy of GER treatment in improving
childhood-asthma outcomes especially in a well recognized co-
hort of children with difﬁcult-to-treat-asthma associated with
GER. In our previous study, we found that 12 weeks of
esomeprazole signiﬁcantly improved C-ACT and reduces the
induced sputum SP but it did not improve the FEV1 (% of pre-
dicted) or PEF variability. So, in the current study we aimed to
investigate the effect of adding domperidone to the esomepraz-
ole anti-GER therapy on the pulmonary functions and the C-
ACT.
There is growing evidence that GER is related mainly to
motility disorders and not only due to acid hypersecretion.
The main pathological factor in the development of GER is
lower esophageal sphincter dysfunction. Delayed gastric emp-
tying and decreased esophageal peristalsis are other important
contributing factors [19].
Many studies investigated the effects of proton pump inhib-
itors (PPI) effects on improving the asthma symptoms andpulmonary functions [20–22]. However, fewer studies investi-
gated the efﬁcacy of combination of PPI and gastrointestinal
prokinetic drugs in improving the asthma symptoms and pul-
monary functions [23,24]. However, up to the best of our
knowledge, the current study is the ﬁrst study which investi-
gated the efﬁcacy of combination of both esomeprazole and
domperidone in asthmatic children with GER.
In the current study, we found that adding domperidone to
esomeprazole signiﬁcantly improved C-ACT, and reduced the
induced sputum SP in children with difﬁcult-to-treat asthma
associated with GER. The FEV1 (% of predicted) showed a
signiﬁcant improvement in the subgroup with combined treat-
ment with esomeprazole and domperidone than the subgroup
treated with esomeprazole alone. We also observed more
improvement of endoscopic reﬂux scores in children who re-
ceived combination therapy than who received esomeprazole
only.
Domperidone is a prokinetic peripheral dopamine D2-
receptor antagonist that increases motility and gastric
emptying which is used to treat slowed movement in the gas-
trointestinal tract associated with various gastrointestinal
motility disorders. It decreases postprandial reﬂux time and
is therefore used to treat regurgitation and vomiting [25].
The add on effect of domperidone to the effect of esomep-
razole observed in the current study in improving the C-ACT
and pulmonary function can be explained by combination syn-
ergistic effect of decreasing acid production as well as increas-
ing lower esophageal tone and esophageal clearance thus
producing a better therapeutic response [26]. Normalizing the
underlying dysmotility or augmenting existing motility would
decrease esophageal acid contact time, decreasing the risk of
acid aspiration and hence decrease airway inﬂammation and
improve the pulmonary functions [26–28]. Dupont et al. found
that the use of domperidone provided a satisfactory control of
nocturnal GOR and therefore emerges as a valuable agent for
the treatment of chronic GOR-associated respiratory disorders
in childhood [28].
Sharma et al. found that the combined therapy with ome-
prazole and domperidone for 16 weeks in asthmatics with
GER may be beneﬁcial by reducing asthma symptoms and res-
cue medication use, as well as improving pulmonary function.
However, their study was conducted in the adult asthmatics of
various subtypes and used the combination therapy for
16 weeks [24]. However, Yan-hong et al. [29], found the same
beneﬁcial effects of the combined therapy with omeprazole
and domperidone but in asthmatic children with no signiﬁcant
side effects of such combination [29].
Limitations of the study
The ﬁrst limitation in the current study is that we did not an-
swer the question about the efﬁcacy of adding H2 receptor
antagonist to the poly therapy in improving C-ACT and the
pulmonary functions in asthmatic children. Still we need to
determine the cut-off point for sputum SP that is more sensi-
tive to detect the presence of GER in asthmatic children. An-
other limitation of the current study is using endoscopy for
diagnosing GER not pH or impedance studies that may be
more helpful as there will be some false negative cases with
the use of endoscopy. Endoscopy was used because it was
the available tool in our hospital.
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Gastro-esophageal reﬂux (GER) is a frequent association with
childhood difﬁcult-to-treat asthma as it was observed in about
45% of them. Combination of domperidone and esomeprazole
was more effective in improving the endoscopic reﬂux score,
childhood-asthma control test (C-ACT) and FEV1 (% of pre-
dicted) and signiﬁcantly reduced the sputum SP than the single
use of esomeprazole in children with difﬁcult-to-treat asthma.
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